Patents Examined by Taylor V. Oh
  • Patent number: 10648013
    Abstract: Provided is a compound that comprises the structure: where SIG is a signaling molecule and R3 is a formyl, a succinyl, a methyl succinyl, or a myristoyl. Also provided is a kit is provided that comprises the above compound, with instructions for determining the presence of the enzyme. Additionally, a method is provided for determining whether a sample has an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ?-amino of a lysine. Also provided is a method of determining whether a molecule inhibits an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ?-amino of a lysine.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 12, 2020
    Assignee: Enzo Life Sciences, Inc.
    Inventors: Konrad T. Howitz, Zhongda Zhang, Anne Kisielewski, Elizabeth Dale, Wayne Forrest Patton
  • Patent number: 10640477
    Abstract: This invention relates to a process for the epoxidation of a tetrasubstituted alkene such as terpinolene to the corresponding epoxide such as terpinolene epoxide by reacting the tetrasubstituted alkene with peracetic acid prepared in situ from acetic anhydride and hydrogen peroxide in the presence of at least one buffering agent. Further, the invention relates to the use of an oxidizing agent comprising hydrogen peroxide and acetic anhydride for the in-situ epoxidation of a tetrasubstituted alkene.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: May 5, 2020
    Assignee: BASF AGRO B.V.
    Inventors: Michael Rack, Joachim Gebhardt, Bernd Wolf, Stefan Benson, Roland Goetz, Helmut Kraus
  • Patent number: 10640478
    Abstract: The invention relates to a method for obtaining glycidol in a semi-continuous or continuous manner by decarboxylating glycerol carbonate at reduced pressure, at a temperature less than or equal to 130° C. and in the presence of alkoxide catalysts of alkaline metals and alkaline earth metals, metal oxides, mixed metal oxides, metal stannates and mixed metal stannates, all of which optionally supported via SiO2, ?-Al2O3, MgO and ZrO2.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: May 5, 2020
    Assignee: FUNDACION TECNALIA RESEARCH & INNOVATION
    Inventors: José Ramón Ochoa Gómez, Olga Gómez De Miranda Jiménez De Aberastui, Noelia Blanco Pérez, Belén Maestro Madurga, Soraya Prieto Fernández
  • Patent number: 10639381
    Abstract: Provided herein are trioxacarcin-antibody drug conjugates of Formula (A): and pharmaceutically acceptable salts thereof, comprising at least one instance of the group -L1-(A-L2)a-B attached thereto, wherein a is an integer between 1 and 10, inclusive, L1 is absent or is a linking group, A is a moiety formed from the reaction of two complimentary groups (X and Y), L2 is absent or is another linking group, and B is an antibody or antibody fragment. Also provided are methods of preparing these antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the trioxacarcin-antibody drug conjugates, novel trioxacarcins without an antibody conjugated thereto, pharmaceutical compositions thereof, and methods of their use and treatment.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: May 5, 2020
    Inventors: Andrew G. Myers, Daniel J. Smaltz, Andreas Schumacher
  • Patent number: 10633391
    Abstract: Provided is a diol that excels in thermal stability; and, a method for manufacturing a diol, a di(meth)acrylate, and a method for manufacturing a di(meth)acrylate. The diol represented by the formula (1) below; wherein each of R1 and R2 independently represents a hydrocarbon group; and each R3 independently represents a hydrogen atom, hetero atom-containing group, halogen atom, straight chain alkyl group having 1 to 6 carbon atoms, branched alkyl group having 3 to 6 carbon atoms or, aryl group-containing group having 6 to 12 carbon atoms.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: April 28, 2020
    Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC.
    Inventors: Hideyuki Sato, Atsushi Okamoto, Taketo Ikeno, Tetsuya Shimo
  • Patent number: 10633314
    Abstract: A method of selective conversion of Abienol, represented by formula 1, to Sclareodiol, represented by formula 2 by ozonolysis and subsequent reduction. The ozonolysis is carried out at temperatures above ?60° C., preferably in nonhalogenated solvents. R is selected from H, acetals, aminals, optionally substituted alkyl groups, such as benzyl group, carboxylates such as acetates or formates, carbonates such as methyl or ethyl carbonates, carbamates, and any protecting group which can be attached to 1 and cleaved from 2, R? is selected from CH?CH2, an alkyl moiety with C2-C20, e.g. CH2—CH3, or a cycloalkyl or polycycloalkyl moiety with C3-C20, e.g. cyclopropyl, optionally alkylated, respectively, and the wavy bond is depicting an unspecified configuration of the adjacent double bond between C2 and C3.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: April 28, 2020
    Assignee: GIVAUDAN S.A.
    Inventor: Fridtjof Schröder
  • Patent number: 10625176
    Abstract: This invention describes a method to extract and separate compounds from plant or animal material in a continuous process. The method uses dimethyl ether as a safe and efficient solvent which will extract polar and non-polar compounds. The extracted compounds are separated by distillation which is configured to provide individual compounds or groups of compounds.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: April 21, 2020
    Inventors: Larry Jack Melnichuk, Karen Sue Kelly
  • Patent number: 10618880
    Abstract: Provided herein are methods of producing dialkylfurans, such as 2,5-dimethylfuran, and other alkyl furans, such as 2-methylfuran. For example, 2,5-dimethylfuran may be produced by reducing (5-methylfuran-2-yl)methanol or 2-(chloromethyl)-5-methylfuran.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: April 14, 2020
    Assignee: MICROMIDAS, INC.
    Inventors: Dimitri A. Hirsch-Weil, Makoto N. Masuno, John Bissell, Dennis A. Hucul, Alex B. Wood, Robert Joseph Araiza, Daniel R. Henton
  • Patent number: 10618889
    Abstract: The present disclosure relates to novel thiophene monoamine based organic-inorganic hybrid perovskites, and the method of making and using the novel organic-inorganic hybrid perovskites.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: April 14, 2020
    Assignee: Purdue Research Foundation
    Inventors: Letian Dou, Yao Gao
  • Patent number: 10618922
    Abstract: Embodiments of the present disclosure provide for biaryl ligands (also referred to herein as “biaryl compound”), biaryl complexes, methods of making biaryl compounds, methods of making single enantiomers of these biaryl compounds, methods of use (e.g., catalysis), and the like.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: April 14, 2020
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Aaron Aponick, Flavio S. P. Cardoso
  • Patent number: 10611746
    Abstract: The invention addresses the problem of providing a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione that is suited to industrial production. The invention provides a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione by reacting 3-bromo-3-buten-2-one and 2-hydroxy-1,4-naphthoquinone in the presence of a solvent, then obtaining crystals of 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione by adding an alcohol-based solvent and/or water to the reaction system, and treating the crystals by using a specific adsorbent in the presence of a solvent.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: April 7, 2020
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Toshikazu Yagi, Satoshi Suzuki, Hiroto Tatamidani, Kazuki Hashimoto
  • Patent number: 10596179
    Abstract: Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE). Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: March 24, 2020
    Assignee: Celgene Corporation
    Inventors: Peter H. Schafer, Lei Wu, Ying Ye
  • Patent number: 10597687
    Abstract: This disclosure describes biosynthesized compounds including anhydromevalonolactone and ?-methyl-?-valerolactone. This disclosure further describes biosynthetic methods for making these compounds. In some embodiments, the biosynthetic methods can include a combination of biosynthesis and chemical steps to produce ?-methyl-?-valerolactone. Finally, this disclosure described recombinant cells useful for the biosynthesis of these compounds.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: March 24, 2020
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Kechun Zhang, Mingyong Xiong
  • Patent number: 10597374
    Abstract: The integrated process comprises a step a) of dehydrogenating propane providing a stream S1 comprising propane and propene; a step b) of separating stream S1 in at least one rectification column, providing an overhead product stream S2 comprising more than 99% by weight propene, a side stream S3 comprising from 90 to 98% by weight propene and a bottoms product stream S4 enriched in propane; a step c) of reacting propene with hydrogen peroxide in the presence of an epoxidation catalyst using propene in molar excess; and a step d) of separating non-reacted propene and propene oxide from the reaction mixture of step c) providing a propene oxide product and a stream S5 comprising propene and propane; wherein stream S3 is passed to step c), stream S5 is recycled to step b) and stream S4 is recycled to step a).
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: March 24, 2020
    Assignees: Evonik Operations GmbH, thyssenkrupp Industrial Solutions AG
    Inventors: Holger Wiederhold, David Bolz, Georg Friedrich Thiele
  • Patent number: 10597398
    Abstract: To obtain a novel therapeutic drug for a malignant tumor or fibrosis. Used is a compound represented by formula (1), a salt thereof, or a solvate thereof. Also used is a therapeutic drug for a malignant tumor or a therapeutic drug for fibrosis, comprising a compound represented by formula (1), a salt thereof, or a solvate thereof.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: March 24, 2020
    Assignees: National University Corporation Tottori University, KanonCure, Inc.
    Inventors: Goshi Shiota, Noriko Itaba, Minoru Morimoto, Hiroyuki Oka, Kenichiro Abe, Hiroki Shimizu, Yohei Kouno, Satoshi Yokogi
  • Patent number: 10588874
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: March 17, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Patent number: 10584107
    Abstract: Disclosed is a process for the extraction of furfural which includes: (a) subjecting a composition comprising furfural, water, at least one acid and an aromatic solvent, with a boiling point higher than that of furfural, to a first separation step providing: (i) an organic phase, and (ii) an aqueous phase; (b) subjecting the aqueous phase of step (a) to a first distillation step to provide: (i) a first in top stream comprising a furfural-water azeotrope; (c) subjecting the first top stream of step (b) to a second separation step to provide: (i) a second top stream comprising a portion of the furfural-water azeotrope; (d) subjecting the second top stream of step (c) to a second distillation step to provide: (i) a third top stream enriched with the furfural-water azeotropic mixture; (e) subjecting the organic phase of step (a) to a third distillation step to provide: a fourth top stream comprising furfural.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: March 10, 2020
    Assignee: SHELL OIL COMPANY
    Inventors: Juben Nemchand Chheda, Charu Ehrenreich-Gureja, Jean Paul Andre Marie Joseph Ghislain Lange
  • Patent number: 10562874
    Abstract: A process for the extraction of furfural from a composition comprising furfural, water, at least one organic acid and an oxygenate solvent with a boiling point higher than that of furfural. The process includes: (a) subjecting the composition to a first liquid-liquid separation step to provide: (i) an organic phase; (b) subjecting the organic phase of step (a) to a first distillation step to provide: (i) a first top stream; (c) subjecting the first top stream of step (b) to a second liquid-liquid separation step to provide: (i) a second top stream; and (d) subjecting the second top stream of step (c) to a second distillation step to provide: (i) a third top stream comprising a furfural-water azeotrope, and (ii) a third bottom stream comprising furfural.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: February 18, 2020
    Assignee: SHELL OIL COMPANY
    Inventors: Juben Nemchand Chheda, Charu Ehrenreich-Gureja, Jean Paul Andre Marie Joseph Ghislain Lange
  • Patent number: 10562837
    Abstract: The invention relates to a method for preparing a compound comprising two phenyl groups by reacting a bisfuranic compound with a dienophile; and to such compounds.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: February 18, 2020
    Assignee: Nederlandse Organisatie voor toegepast-natuurwetenschappelijk onderzoek TNO
    Inventors: Marc Crockatt, Jan Harm Urbanus, Paul Mathijs Könst
  • Patent number: 10548900
    Abstract: A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: February 4, 2020
    Assignees: MITOCHON PHARMACEUTICALS, INC., BIOVENTURES, LLC
    Inventors: John Gerard Geisler, Robert Alonso, Peter Anthony Crooks, Narsimha Reddy Penthala, Zaineb Albayati